HYPERTHERMIA FOR SOFT TISSUE SARCOMA
THE ISSELS RCT AND 10-YEAR OUTCOMES
The landmark Issels phase III trial proved that adding regional hyperthermia to neoadjuvant chemotherapy improves long-term survival in high-risk soft tissue sarcoma β reshaping European sarcoma practice.
analyticsAt a Glance
- check_circlePhase III RCT: EORTC 62961βESHO 95, 341 patients (Lancet Oncol 2010)
- check_circleLocal progression-free survival improved by 30% with added hyperthermia
- check_circle10-year overall survival: 52.6% vs 42.7% (JAMA Oncol 2018)
- check_circleNow part of ESMO sarcoma guidelines for high-risk localized disease
Why High-Risk Soft Tissue Sarcoma Is So Challenging to Treat
Soft tissue sarcomas are rare and biologically aggressive. For the high-risk group β large, deep, high-grade tumours β surgery and radiation alone leave many patients with local recurrence and distant metastases, and standard chemotherapy benefit has been modest. This is the gap the Issels trial was designed to close.
βFor high-risk sarcoma, the question was never whether more treatment was needed β it was whether anything new could meaningfully improve long-term outcomes. Hyperthermia + chemotherapy gave the field its first clear answer in a generation.β
High-Risk Disease: Large, Deep, High-Grade
High-risk soft tissue sarcoma is defined as FNCLCC grade 2 or 3, β₯5 cm in size, and deep to fascia. These tumours have 5-year overall survival of approximately 50% with conventional treatment and frequently recur both locally and distantly despite optimal surgery and radiation.
Standard Chemotherapy Benefit Has Been Modest
Doxorubicin-based regimens have been the backbone of sarcoma chemotherapy for decades. Multiple trials have struggled to demonstrate clear survival benefit from adjuvant chemotherapy. The Issels trial addressed this by combining intensive chemotherapy with hyperthermia to amplify drug effect at the tumour site.
The Issels Trial: Study Design (EORTC 62961βESHO 95)
Led by Rolf Issels at LMU Munich and conducted jointly by the EORTC Soft Tissue and Bone Sarcoma Group and ESHO, the trial enrolled 341 patients across European centres over a decade. The design and results were published in The Lancet Oncology in 2010 and updated in JAMA Oncology in 2018.
Multi-Centre Phase III Randomised Controlled Trial
The trial randomised 341 patients with high-risk localised soft tissue sarcoma across nine European centres specialised in regional hyperthermia and sarcoma surgery. Enrolment ran from 1997 to 2006, with primary results published in 2010 and long-term follow-up in 2018.
Eligibility: High-Risk Localised Sarcoma
Eligible patients had FNCLCC grade 2 or 3 soft tissue sarcoma, tumour size β₯5 cm, and deep location relative to fascia. Both extremity sarcomas and abdominal or retroperitoneal sarcomas were included. Patients were either primarily inoperable or had been incompletely resected (R1/R2 status).
Treatment Arms: Chemotherapy vs Chemotherapy + Hyperthermia
The control arm received 4 cycles of neoadjuvant EIA chemotherapy (etoposide 125 mg/mΒ², ifosfamide 1500 mg/mΒ², doxorubicin 50 mg/mΒ²), then local therapy (surgery Β± radiation), then 4 more EIA cycles. The experimental arm received the identical chemotherapy plus regional hyperthermia paired with each chemotherapy cycle.
Hyperthermia Protocol: Deep Regional, Twice Per Cycle
Regional hyperthermia was delivered using the BSD-2000 phased-array system or equivalent equipment. Two 60-minute sessions of heating (target temperature 40β43Β°C) were paired with each chemotherapy cycle β typically given on day 1 and day 4 of each cycle, synchronised with the chemotherapy infusion.
Primary Endpoint: Local Progression-Free Survival
The pre-specified primary endpoint was local progression-free survival (LPFS) β time from randomisation to local recurrence, progression, or death from any cause. Secondary endpoints included disease-free survival, overall survival, response rate, and treatment toxicity.
Trial Outcomes: Survival and Response
Headline results from the 2010 Lancet Oncology publication, with sustained 10-year follow-up data published in JAMA Oncology in 2018.
Local Progression-Free Survival at 5 Years (Primary Endpoint)
Proportion of patients free of local progression or death at 5 years.
- Chemotherapy Alone61%
- Chemotherapy + Regional Hyperthermia76%
Disease-Free Survival at 5 Years
Proportion of patients free of any recurrence (local or distant) or death at 5 years.
- Chemotherapy Alone32%
- Chemotherapy + Regional Hyperthermia47%
Overall Survival at 5 Years
Proportion of patients alive 5 years after randomisation.
- Chemotherapy Alone51.3%
- Chemotherapy + Regional Hyperthermia62.7%
Overall Survival at 10 Years (Long-Term Follow-Up)
Proportion of patients alive 10 years after randomisation β confirms sustained survival benefit.
- Chemotherapy Alone42.7%
- Chemotherapy + Regional Hyperthermia52.6%
The 10-Year Follow-Up: JAMA Oncology 2018
The updated long-term analysis published eight years after the original report confirmed durable benefit from the addition of regional hyperthermia, making the Issels trial one of the few phase III studies in hyperthermia oncology to demonstrate overall survival improvement.
- 0.73Hazard Ratio for Overall SurvivalFavouring chemotherapy + hyperthermia (95% CI: 0.56β0.94). Statistically significant.
- 11.6 yrsMedian Follow-Up DurationLong enough to capture late recurrences and confirm durability of the survival benefit.
- 52.6%10-Year Overall Survival (HT Arm)Compared with 42.7% for chemotherapy alone β a 9.9 percentage point absolute survival gain.
- 0.65Hazard Ratio for Local Progression-Free SurvivalSustained local control advantage at long-term follow-up; clinically and statistically significant.
Modern Treatment Approach: How Hyperthermia Fits Into Sarcoma Care
Following the Issels results, regional hyperthermia is incorporated into European sarcoma practice and ESMO guidelines for selected high-risk patients. Here is how it is typically used today.
| Clinical Scenario | Standard Approach | Role of Hyperthermia |
|---|---|---|
| High-risk extremity sarcoma (β₯5 cm, G2/G3, deep) | Neoadjuvant chemotherapy + limb-sparing surgery + radiation | Adding regional hyperthermia improves LPFS and OS (Issels evidence) |
| Retroperitoneal / abdominal sarcoma | Surgical resection Β± preoperative radiation; chemotherapy controversial | Hyperthermia + chemo studied in this subgroup; particularly relevant for borderline-resectable disease |
| Borderline-resectable or marginal-resection sarcoma (R1) | Repeat surgery, adjuvant radiation, or re-resection considerations | Neoadjuvant chemo + hyperthermia can downstage tumours and improve resectability |
| Recurrent local sarcoma after prior surgery and radiation | Re-resection, palliative chemotherapy, or systemic therapy | Regional hyperthermia + low-dose re-irradiation or chemotherapy in salvage settings |
| Low-grade or small (<5 cm) sarcoma | Wide local excision Β± radiation; chemotherapy generally not indicated | Hyperthermia not routinely used β surgery alone provides adequate control |
| Metastatic sarcoma | Systemic chemotherapy Β± targeted agents | Hyperthermia not standard; investigational in oligometastatic disease |
Accessing Hyperthermia for Soft Tissue Sarcoma
The Issels protocol requires coordinated multi-disciplinary care β chemotherapy, regional hyperthermia, surgery, and radiation β typically only available at specialist sarcoma centres. Here is the practical pathway.
- 1
Submit Imaging, Pathology, and Sarcoma Subtype
Recent MRI of the primary tumour, CT chest for staging, full pathology with FNCLCC grade, immunohistochemistry, and molecular subtyping (where available) are needed to confirm high-risk status and plan treatment.
- 2
Multi-Disciplinary Sarcoma Board Review
A sarcoma MDT β surgical oncologist, medical oncologist, radiation oncologist, hyperthermia specialist, pathologist, and radiologist β evaluates resectability, neoadjuvant strategy, and the role of hyperthermia. Sarcoma decisions require this team review.
- 3
Neoadjuvant Chemotherapy + Hyperthermia (4 Cycles)
Four cycles of EIA (or modern equivalent) chemotherapy are delivered every 3 weeks, each paired with two regional hyperthermia sessions. The hyperthermia is delivered using a BSD-2000 phased-array system synchronised with chemotherapy infusion.
- 4
Surgical Resection Β± Radiation
After neoadjuvant therapy, the tumour is reassessed and resected with the goal of negative margins. Postoperative radiation is delivered for marginal or close resections, particularly in extremity tumours.
- 5
Adjuvant Chemotherapy + Hyperthermia (4 Cycles)
After surgical recovery, an additional 4 cycles of EIA chemotherapy + regional hyperthermia complete the planned regimen. The total treatment duration including all phases is approximately 8β10 months.
Related Treatments & Resources
Explore the full hyperthermia knowledge base and related cancer treatment pages.
- Hyperthermia Therapy β Full Treatment Page
- Deep Regional Hyperthermia: Heating Tumours Inside the Pelvis and Abdomen
- How Heat Makes Chemotherapy Work Better: Drug-Heat Interactions
- Thermotolerance: Why Sessions Must Be Spaced 72 Hours Apart
- Hyperthermia for Cervical Cancer: van der Zee Trial and Outcomes
- Hyperthermia for Chest Wall Breast Cancer Recurrence: ESHO Evidence
Frequently Asked Questions
Common questions from patients and caregivers about hyperthermia for soft tissue sarcoma.
About the Trial and Evidence
Is the Issels trial still relevant today, more than a decade after publication?
Yes β the 2018 JAMA Oncology long-term follow-up confirmed sustained 10-year survival benefit (52.6% vs 42.7%) with hazard ratio 0.73. The evidence base is among the strongest in hyperthermia oncology and is now incorporated into ESMO sarcoma guidelines. The trial remains the definitive phase III evidence for adding regional hyperthermia to neoadjuvant chemotherapy in high-risk soft tissue sarcoma.
How does the Issels trial compare to other sarcoma chemotherapy trials?
Unlike many adjuvant chemotherapy trials in sarcoma that have shown inconsistent survival benefit, the Issels trial demonstrated clear improvement in local control, disease-free survival, and overall survival at both 5 and 10 years. The integration of regional hyperthermia is what distinguishes this trial β and what plausibly explains the consistent and durable effect.
Does the trial apply to all sarcoma subtypes?
The Issels trial enrolled patients with a range of soft tissue sarcoma histologies, predominantly high-grade pleomorphic sarcoma, leiomyosarcoma, synovial sarcoma, and liposarcoma. The benefit was generally consistent across subtypes. Specific rare histologies (e.g., gastrointestinal stromal tumours, dermatofibrosarcoma protuberans) were not the focus and have different optimal treatment paths.
Are there newer trials building on the Issels results?
Yes. Modern protocols increasingly incorporate doxorubicin + ifosfamide (without etoposide) plus regional hyperthermia, reflecting evolution in sarcoma chemotherapy. Studies are also examining hyperthermia combined with targeted agents and checkpoint inhibitors in selected sarcoma subtypes. The Issels trial remains the foundational evidence on which these modern protocols are built.
For Patients Considering Treatment
Am I a candidate for the Issels protocol?
Strong candidates have biopsy-confirmed high-risk soft tissue sarcoma (FNCLCC grade 2 or 3, β₯5 cm, deep), are fit for intensive chemotherapy, have no distant metastases (or limited oligometastatic disease in some protocols), and have anatomic access to regional hyperthermia equipment. CancerFax can review your pathology and imaging to determine eligibility.
Where can I access this treatment?
The original Issels trial centres in Germany β LMU Munich, CharitΓ© Berlin, Erlangen, and others β remain leaders in this protocol. Additional European centres in the Netherlands, Italy, and Austria also offer it. China has rapidly developed sarcoma hyperthermia programmes at major cancer hospitals in Beijing, Shanghai, and Guangzhou. Selected Indian centres also provide regional hyperthermia for sarcoma.
How long is the entire treatment course?
The full Issels protocol takes 8β10 months: 4 cycles of neoadjuvant chemotherapy + hyperthermia (3 months), surgical recovery (4β8 weeks), 4 cycles of adjuvant chemotherapy + hyperthermia (3 months), and any required radiation. International patients typically need to plan for multiple treatment stays or extended duration abroad.
What about retroperitoneal sarcoma specifically?
Retroperitoneal sarcoma is one of the most challenging sarcoma subtypes due to anatomic complexity and difficulty achieving negative margins. Regional hyperthermia + chemotherapy is particularly relevant here because the retroperitoneum sits within reach of deep regional hyperthermia systems. Multiple European and Chinese centres have developed dedicated protocols for retroperitoneal sarcoma incorporating hyperthermia.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering Hyperthermia for Soft Tissue Sarcoma Treatment?
Upload your imaging, pathology, and treatment history. Our oncology team will review your case to determine whether the Issels-based protocol β neoadjuvant chemotherapy + regional hyperthermia β is suitable for your sarcoma and identify the right specialist centre.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.